Expansion of Intravenous Tissue Plasminogen Activator Eligibility Beyond National Institute of Neurological Disorders and Stroke and European Cooperative Acute Stroke Study III Criteria.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Neurologic clinics

• Publication date

  2015-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ncl.2015.01.004PMID 25907912
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Stroke: Highlights of Selected Articles

  2015cited by this paper
• Preexisting dual antiplatelet treatment increases the risk of post-thrombolysis intracranial hemorrhage in Chinese stroke patients

  2015cited by this paper
• Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data

  2015cited by this paper
• [Successful thrombolysis without hemorrhage in a patient with cardioembolic stroke under dabigatran treatment-a case report and review of literature].

  2014cited by this paper
• Intravenously administered tissue plasminogen activator useful in milder strokes? A meta-analysis.

  2014cited by this paper
• Successful thrombolysis of stroke with intravenous alteplase in the third trimester of pregnancy

  2014cited by this paper
• Safe intravenous thrombolysis in acute stroke despite treatment with rivaroxaban.

  2014cited by this paper
• Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Apixaban

  2014cited by this paper
• The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Protocol: A Randomized, Blinded, Efficacy Trial of Standard vs. Intensive Hyperglycemia Management in Acute Stroke

  2014cited by this paper
• Revascularization for acute ischemic stroke is safe for rivaroxaban users.

  2014cited by this paper
• Thrombolysis in Patients With Mild Stroke: Results From the Austrian Stroke Unit Registry

  2014cited by this paper
• Good outcome after intravenous thrombolysis for acute stroke in a patient under treatment with dabigatran.

  2014cited by this paper
• Aortic transgraft hemorrhage after intravenous tissue plasminogen activator therapy in patients with acute ischemic stroke.

  2014cited by this paper
• Stroke: Highlights of Selected Articles

  2014cited by this paper
• Off-label thrombolysis versus full adherence to the current European Alteplase license: impact on early clinical outcomes after acute ischemic stroke

  2014cited by this paper
• Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-Hour Exclusions and Association With Outcome: Data From Get With The Guidelines-Stroke

  2014cited by this paper
• Time to treatment with recombinant tissue plasminogen activator and outcome of stroke in clinical practice: retrospective analysis of hospital quality assurance data with comparison with results from randomised clinical trials

  2014cited by this paper
• Safety of Thrombolysis in Patients With Acute Ischemic Stroke and Cerebral Cavernous Malformations

  2014cited by this paper
• Intravenous thrombolysis in stroke patients receiving rivaroxaban

  2014cited by this paper
• Intravenous thrombolysis for acute ischaemic stroke in the setting of rivaroxaban use.

  2014cited by this paper
• Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke.

  2014cited by this paper
• Preexisting Cerebral Microbleeds on Susceptibility-Weighted Magnetic Resonance Imaging and Post-Thrombolysis Bleeding Risk in 392 Patients

  2014cited by this paper
• Number of Cerebral Microbleeds and Risk of Intracerebral Hemorrhage After Intravenous Thrombolysis

  2014cited by this paper
• 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

  2014cited by this paper
• Review, Historical Context, and Clarifications of the NINDS rt-PA Stroke Trials Exclusion Criteria: Part 1 Rapidly Improving Stroke Symptoms

  2013cited by this paper
• Safety of off‐label stroke treatment with tissue plasminogen activator

  2013cited by this paper
• Successful thrombolysis in postoperative patients with acute massive pulmonary embolism.

  2013cited by this paper
• Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.

  2013cited by this paper
• Presentation and outcomes of "wake-up strokes" in a large randomized stroke trial: analysis of data from the International Stroke Trial.

  2013cited by this paper
• Thrombolysis Despite Recent Stroke: A Case Series

  2013cited by this paper
• Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

  2013cited by this paper
• Intravenous Thrombolysis in a Stroke Patient Receiving Rivaroxaban

  2013cited by this paper
• TPA for ischemic stroke in patients ≥80 years

  2013cited by this paper
• Thrombolysis in a Stroke Patient on Dabigatran Anticoagulation: Case Report and Synopsis of Published Cases

  2013cited by this paper
• Systemic thrombolysis for stroke in pregnancy.

  2013cited by this paper
• Successful intravenous thrombolysis in acute ischaemic stroke in a patient on rivaroxaban treatment

  2013cited by this paper
• A Case-Controlled Comparison of Thrombolysis Outcomes Between Wake-Up and Known Time of Onset Ischemic Stroke Patients

  2013cited by this paper
• The exact science of stroke thrombolysis and the quiet art of patient selection.

  2013cited by this paper
• Safety of intravenous thrombolysis in acute ischemic stroke patients with saccular intracranial aneurysms.

  2013cited by this paper
• An Observational Study of Thrombolysis Outcomes in Wake-Up Ischemic Stroke Patients

  2013cited by this paper
• Exclusion criteria for intravenous thrombolysis in stroke mimics: an observational study.

  2013cited by this paper
• Clinical outcomes of fast MRI-based trombolysis in wake-up strokes compared to superacute ischemic strokes within 12 hours

  2013cited by this paper
• Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial

  2013cited by this paper
• Thrombolysis for Acute Ischemic Stroke in Patients With Cancer: A Population Study

  2013cited by this paper
• Stroke: Highlights of Selected Articles

  2013cited by this paper
• Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin

  2013cited by this paper
• Stroke thrombolysis in England: an age stratified analysis of practice and outcome.

  2013cited by this paper
• Wake-up stroke within 3 hours of symptom awareness: imaging and clinical features compared to standard recombinant tissue plasminogen activator treated stroke.

  2013cited by this paper
• Validation of minor stroke definitions for thrombolysis decision making.

  2013cited by this paper
• Too Good to Treat? Outcomes in Patients Not Receiving Thrombolysis Due to Mild Deficits or Rapidly Improving Symptoms

  2012cited by this paper
• The Safety of Intravenous Thrombolysis for Ischemic Stroke in Patients With Pre-Existing Cerebral Aneurysms: A Case Series and Review of the Literature

  2012cited by this paper
• Off‐label intravenous thrombolysis in acute stroke

  2012cited by this paper
• Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population: The Effect of the European Cooperative Acute Stroke Study (ECASS) III Trial

  2012cited by this paper
• La tomografía computarizada de perfusión permite superar importantes criterios de exclusión SITS-MOST para la trombólisis endovenosa del infarto cerebral

  2012cited by this paper
• Intravenous thrombolysis in a stroke patient taking dabigatran.

  2012cited by this paper
• Thrombolysis in an Ischemic Stroke Patient on Dabigatran Anticoagulation: A Case Report

  2012cited by this paper
• Intravenous thrombolysis for acute cerebral ischaemia in old stroke patients ≥80 years of age

  2012cited by this paper
• [Perfusion computed tomography makes it possible to overcome important SITS-MOST exclusion criteria for the endovenous thrombolysis of cerebral infarction].

  2012cited by this paper
• How to identify stroke mimics in patients eligible for intravenous thrombolysis?

  2012cited by this paper
• Detection and Significance of Incidental Unruptured Cerebral Aneurysms in Patients Undergoing Intravenous Thrombolysis for Acute Ischemic Stroke

  2012cited by this paper
• Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke

  2012cited by this paper
• Off-Label Thrombolysis for Acute Ischemic Stroke: Rate, Clinical Outcome and Safety Are Influenced by the Definition of ‘Minor Stroke’

  2011cited by this paper
• DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4·5 h of symptom onset (PRE-FLAIR): a multicentre observational study.

  2011cited by this paper
• Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of age

  2011cited by this paper
• Initial Stroke Severity Is the Major Outcome Predictor for Patients Who Do Not Receive Intravenous Thrombolysis due to Mild or Rapidly Improving Symptoms

  2011cited by this paper
• Outcomes in Mild or Rapidly Improving Stroke Not Treated With Intravenous Recombinant Tissue-Type Plasminogen Activator: Findings From Get With The Guidelines–Stroke

  2011cited by this paper
• Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United States: A Doubling of Treatment Rates Over the Course of 5 Years

  2011cited by this paper
• Safety and Outcomes of Intravenous Thrombolysis in Stroke Mimics: A 6-Year, Single-Care Center Study and a Pooled Analysis of Reported Series

  2011cited by this paper
• Fatal Intracerebral Hemorrhage Associated with Administration of Recombinant Tissue Plasminogen Activator in a Stroke Patient on Treatment with Dabigatran

  2011cited by this paper
• Intravenous Thrombolysis Based on Diffusion-Weighted Imaging and Fluid-Attenuated Inversion Recovery Mismatch in Acute Stroke Patients with Unknown Onset Time

  2011cited by this paper
• Population-based study of wake-up strokes

  2011cited by this paper
• Subtherapeutic International Normalized Ratio in Warfarin-Treated Patients Increases the Risk for Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis

  2011cited by this paper
• Hemorrhagic complications after systemic thrombolysis in acute stroke patients with abnormal baseline coagulation

  2011cited by this paper
• Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials.

  2010cited by this paper
• Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke.

  2010cited by this paper
• FLAIR can estimate the onset time in acute ischemic stroke patients.

  2010cited by this paper
• Feasibility and Safety of Magnetic Resonance Imaging-Based Thrombolysis in Patients with Stroke on Awakening: Initial Single-Centre Experience

  2010cited by this paper
• Off-Label Thrombolysis Is Not Associated With Poor Outcome in Patients With Stroke

  2010cited by this paper
• Hemispheric hypoperfusion in postictal paresis mimics early brain ischemia.

  2010cited by this paper
• Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Dabigatran

  2010cited by this paper
• Does Current Oral Antiplatelet Agent or Subtherapeutic Anticoagulation Use Have an Effect on Tissue-Plasminogen-Activator-Mediated Recanalization Rate in Patients with Acute Ischemic Stroke?

  2010cited by this paper
• Clinical impact of MRI perfusion disturbances and normal diffusion in acute stroke patients.

  2009cited by this paper
• Thrombolytic Therapy for Patients Who Wake-Up With Stroke

  2009cited by this paper
• Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association.

  2009cited by this paper
• Treatment Time-Specific Number Needed to Treat Estimates for Tissue Plasminogen Activator Therapy in Acute Stroke Based on Shifts Over the Entire Range of the Modified Rankin Scale

  2009cited by this paper
• Thrombolysis in Childhood Stroke: Report of 2 Cases and Review of the Literature

  2009cited by this paper
• Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic stroke

  2009cited by this paper
• Acute Hyperglycemia and Early Hemorrhagic Transformation in Ischemic Stroke

  2009cited by this paper
• Pre–Tissue Plasminogen Activator Blood Pressure Levels and Risk of Symptomatic Intracerebral Hemorrhage

  2009cited by this paper
• Relationship of Blood Pressure, Antihypertensive Therapy, and Outcome in Ischemic Stroke Treated With Intravenous Thrombolysis: Retrospective Analysis From Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR)

  2009cited by this paper
• Systemic thrombolysis for acute massive pulmonary embolism in the immediate postoperative period after bariatric surgery.

  2009cited by this paper
• Thrombolysis in Stroke Mimics: Frequency, Clinical Characteristics, and Outcome

  2009cited by this paper
• Transient Ischemic Attack Patients with Fluctuations Are at Highest Risk for Early Stroke

  2009cited by this paper
• Thrombolysis in patients with marked clinical fluctuations in neurologic status due to cerebral ischemia.

  2008cited by this paper
• Guidelines for management of ischaemic stroke and transient ischaemic attack 2008.

  2008cited by this paper
• Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke.

  2008cited by this paper
• Identification of nonischemic stroke mimics among 411 code strokes at the University of California, San Diego, Stroke Center.

  2008cited by this paper
• Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

  2008cited by this paper
• Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study.

  2008cited by this paper
• Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial.

  2008cited by this paper

• Identification and Management of Ischemic Stroke in the Postanesthesia Care Unit.

  2019cites this paper
• Why not Intravenous Thrombolysis in Patients with Recurrent Stroke within 3 Months?

  2018cites this paper
• Contraindications with recombinant tissue plasminogen activator (rt-PA) in acute ischemic stroke population

  2018cites this paper
• Influence of ethnic background on left atrial markers of inflammation, endothelial function and tissue remodelling

  2017cites this paper
• Co-morbid conditions in use of recombinant tissue plasminogen activator (rt-PA) for the treatment of acute ischaemic stroke

  2016cites this paper
• And why not thrombolysis in the ambulance (at least for some)?

  2016cites this paper